Mark J. Ratain to Janus Kinase 2
This is a "connection" page, showing publications Mark J. Ratain has written about Janus Kinase 2.
Connection Strength
0.778
-
Subcutaneous Atezolizumab: A Jab Without a Benefit. Clin Pharmacol Drug Dev. 2022 01; 11(1):134-135.
Score: 0.778
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.